Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesity

Roche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide.

The company describes petrelintide as having a potentially best-in-class safety profile, while enicepatide is positioned to deliver strong efficacy. By pairing the two, Roche hopes to achieve synergistic weight-loss outcomes.

If the trial confirms the expected safety and efficacy benefits, the combo could become a competitive product in the crowded obesity market, though results are still pending.